Core Insights - Peli BioThermal is expanding its capabilities in cryogenic transport through the acquisition of Evo Cold Chain from BioLife Solutions, aiming to enhance its position in the growing cell and gene therapy logistics market [1][2] Company Developments - The acquisition of Evo Cold Chain is part of a broader trend in the supply chain and logistics sectors towards strategic consolidation to manage specialized, high-value freight, particularly in the cell therapy market where shipments can exceed $500,000 [2] - Peli BioThermal's integration of Evo's cryogenic shippers and evoIS platform, which provides real-time tracking of shipments and temperature data, complements its existing packaging systems [3] - The acquisition allows Peli BioThermal to offer a more comprehensive range of temperature-controlled solutions, including Crēdo reusable shippers and NanoCool systems, thereby serving a wider segment of the life sciences supply chain [4] Market Context - The global cell and gene therapy market is projected to reach $93 billion by 2030, indicating a significant demand for reliable temperature-controlled logistics solutions [2] - The global cold chain logistics market is expected to exceed $500 billion by 2032, driven by growth in pharmaceuticals, biologics, and precision medicine [5] - Investor interest in logistics providers capable of managing the complexities of cold chain management is increasing, as evidenced by Platinum Equity's involvement with Peli BioThermal [6]